U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07040072) titled 'Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC' on April 18.
Brief Summary: This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent/metastatic HNSCC patients.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
HNSCC
Intervention:
COMBINATION_PRODUCT: Stapokibart and Finotonlimab
Receive the combination of Stapokibart and ...